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Introduction: Pregnant Thai women have low antibody titers against B. pertussis antigens, which coincide
with an increasing incidence of pertussis among Thai infants. Thus, there exists a potential benefit of a
booster dose of tetanus- diphtheria-acellular pertussis (Tdap) vaccine administered during pregnancy.
Here, we report the vaccine reactogenicity profile and birth outcomes in Tdap-vaccinated pregnant
women who have or have not had prior immunization with tetanus vaccine, and the IgG levels to B. per-
tussis antigens in maternal and cord sera at delivery.
Materials and methods: Pregnant women (N = 370) aged 18–40 years were administered the Tdap vaccine
(Boostrix, GlaxoSmithKline, Rixensart, Belgium) at 26–36 weeks gestation. Adverse events following
vaccination were identified by follow-up telephone call and medical record review. IgG against pertussis
toxin (anti-PT), filamentous hemagglutinin (anti-FHA) and pertactin (anti-PRN) in both maternal and
umbilical cord blood obtained at delivery were quantitatively evaluated using enzyme-linked
immunosorbent assay (EUROIMMUN, Lübeck, Germany).
Results: There was no reported increase in the severity or duration of adverse events associated with the
administration of an extra tetanus-containing vaccine within the previous five years (N = 181) or multiple
doses of tetanus-containing vaccines during the current pregnancy (N = 98). Vaccination at least eight
weeks prior to delivery resulted in high antibody titers to all B. pertussis antigens studied.
Conclusions: The reactogenicity of Tdap vaccine administered during pregnancy was not affected by prior
tetanus toxoid immunization. High transplacental antibody against B. pertussis antigens in the cord blood
provides evidence of antibody transfer and should thus help to protect newborns from pertussis during
early life.
 2018 Elsevier Ltd. All rights reserved.1. Introduction
Pertussis is a respiratory disease caused by the gram-negative
bacteria Bordetella pertussis. Although pertussis is vaccine pre-
ventable, new infection readily occurs in both developed and
developing countries despite the implementation of vaccination
efforts worldwide. Severe morbidity and mortality associated withdies to
2 N. Wanlapakorn et al. / Vaccine xxx (2018) xxx–xxxpertussis often occurs in infants and young children [1]. Current
pertussis immunization strategies fail to protect infants who are
too young to have received their primary series of pertussis vacci-
nation. These infants are susceptible to severe pertussis-related
complications and even death due to the lack of protective
immunity.
Passively acquired maternal B. pertussis-specific antibodies are
relatively low and transient in newborns despite an active
transplacental transport [2]. Infants born to Tdap-vaccinated
mothers had significantly higher titers of B. pertussis antibodies
than those born to unvaccinated mothers [3]. Consequently, many
countries including the UK, USA, Spain, Italy, Belgium and Argen-
tina have implemented the Tdap vaccination during pregnancy in
their national immunization programs in order to increase the
maternal B. pertussis antibody levels which will be transplacentally
transferred to protect the newborn during the first months of life
[4–6]. High titers of naturally-acquired maternal-derived B. pertus-
sis antibodies have been shown to interfere with the infant
humoral immune response induced by the whole cell pertussis
(wP) but not to acellular pertussis (aP) vaccine [7]. In contrast,
an interference has been observed in maternal-derived Tdap-
induced anti-B. pertussis antibody in aP-vaccinated infants in clin-
ical studies from the US, Belgium and Vietnam [8–12].
At the April 2014 World Health Organization meeting by the
Strategic Advisory Group of Experts on immunization to prevent
early mortality, researchers concluded that data required for the
implementation of maternal Tdap immunization in countries
where wP vaccine is used in infant vaccination programs could
not be derived from the extrapolated aP vaccine data. Tdap-
induced maternal antibodies may interfere with infant immune
response induced by wP vaccine. Moreover, additional information
on the safety and reactogenicity of repeated tetanus vaccination
are vital to the effective implementation of pertussis immunization
in countries with an existing tetanus vaccination during pregnancy
such as Thailand.
The increasing incidence of pertussis in Thai infants [13],
reportedly low antibody titers to B. pertussis antigens among Thai
pregnant women [14] and the lack of data on potential blunting
after wP vaccine administration in the presence of maternal anti-
bodies, warrant the need to assess the effect of a booster dose of
Tdap vaccination during pregnancy. Here, we report the reacto-
genicity profile of Tdap vaccine in a randomized controlled clinical
trial involving Tdap-vaccinated Thai mothers, and describe the
concentrations of B. pertussis-specific antibodies in paired maternal
and umbilical cord sera. We also report on the adverse events and
pregnancy outcomes when multiple tetanus-containing vaccines
are administered. Further studies regarding the interference of
maternal-derived antibodies in wP-vaccinated infants are ongoing
for this cohort.2. Materials and methods
2.1. Study design
This study was conducted according to the Declaration of Hel-
sinki and Good Clinical Practice Guidelines (ICH-GCP). It was
approved by the Institutional Review Board of the Faculty of Med-
icine, Chulalongkorn University (IRB No. 604/57) and the ethical
committee of the University of Antwerp, Belgium. Written
informed consent was obtained from all pregnant women prior
to enrollment.
This prospective randomized controlled study involved preg-
nant women of Thai citizenship who were offered vaccination with
Tdap vaccine administered between 26 and 36 weeks of gestation
according to the US Advisory Committee on Immunization Prac-Please cite this article in press as: Wanlapakorn N et al. Assessing the reactog
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18–45 years with low obstetrical risks (inclusion and exclusion cri-
teria in Appendix 1) were recruited during routine antenatal visits
at King Chulalongkorn Memorial Hospital in Bangkok between
April 2015 and September 2016. All healthy infants born after
36 weeks of gestation and weighed greater than 2500 g, were
included for the follow-up study (ClinicalTrial.gov
NCT02408926). Ten milliliters of blood were collected from preg-
nant women and the umbilical cord at delivery. Serum was sepa-
rated from whole blood and stored at 20 C prior to testing.
2.2. Study vaccine
Each 0.5 mL dose of the Tdap vaccine (Boostrix, GlaxoSmithK-
line Biologicals, Rixensart, Belgium) contained 2.5 Lf of diphtheria
toxoid (DT), 5 Lf of tetanus toxoid (TT), 8 mg of inactivated pertussis
toxin (PT), 8 mg of formaldehyde-treated filamentous hemagglu-
tinin (FHA) and 2.5 mg of formaldehyde-treated pertactin (PRN)
adjuvanted with aluminium hydroxide. The vaccine was adminis-
tered to pregnant women in the musculus deltoideus by the nurse
or doctor.
2.3. Safety and reactogenicity
Acute adverse reaction was assessed in all women 30 min post-
injection. Research nurses made follow-up telephone calls on day 2
and again on day 7 post-vaccination to record adverse events (AE)
such as redness, pain, and induration at the site of injection, or
fever. Participants were encouraged to report possible AE anytime
thereafter. In instances where AE were reported, daily follow-up
telephone calls were made to record the severity and duration of
AE until symptom resolution. Serious adverse events (SAE) and
pregnancy outcome were recorded for all participants. AEs and
SAEs that occurred after vaccination were evaluated jointly by
the investigators and the data safety monitoring board.
2.4. Laboratory testing
The anti-PT, anti-FHA and anti-PRN IgG titers were analyzed
using commercial ELISA kits (EUROIMMUN, Lübeck, Germany)
according to the manufacturer’s instructions. The ELISA kits used
were calibrated based on the World Health Organization interna-
tional standards. The values were expressed in International Units
(IU) per milliliter. Serum samples were initially diluted 1:101 and
further dilutions were made as needed to yield results within the
detection range. Values below the lower limit of detection (<5 IU/
ml) observed in some samples were calculated as 50% of the cut-
off values (2.5 IU/ml).
2.5. Statistical analysis
The number of pregnant women in this study was calculated
based on the estimation of possible interference of maternal anti-
PT in wP-vaccinated children [7] (significance level = 0.05, power
= 0.90). The IgG levels were expressed as geometric mean concen-
trations (GMC) with 95% confidence interval. Data were analyzed
using SPSS software version 24 (IBM Inc., Armonk, NY, USA) and
R statistical software version 3.4.1. Pearson’s correlation was used
to show the relationship between maternal and cord antibody
titers. The conventional t-test was performed on the antibody log-
arithmic scales to compare the GMC in pregnant women who
received Tdap before and after 30 weeks gestation [16]. The t-test
was also used to test the difference in cord/maternal ratios of anti-
body levels in these two groups. Since the sample sizes of the two
groups were reasonable high, we could rely on the central limit
theorem and hence a conventional t-test would be valid [17]. Toenicity of Tdap vaccine administered during pregnancy and antibodies to
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without prior tetanus immunizations, Mann-Whitney U test was
employed. Assessment of factors affecting cord antibody levels
was performed using a regression approach with the log-
transformed values as the outcome. There were three steps: (1)
variable selection using random forest; (2) backward model selec-
tion based on Akaike Information Criteria (AIC) using multiple lin-
ear regression and (3) further model reduction using likelihood
ratio tests. This procedure was used before for model building
[18]. Antibody titers below the detection limit (censoring observa-
tions) and two extreme outliers of anti-PRN cord-to maternal
ratios were excluded.
3. Results
3.1. Demographic characteristics of the pregnant women and infants
A total of 631 pregnant women were screened, of whom 370
enrolled and were vaccinated with Tdap (Table 1). The majority
of women (93.0%) delivered at full-term. There were 297 (80.3%)
maternal blood and 284 (76.7%) cord blood samples collected at
delivery.
3.2. Reactogenicity profile and pregnancy outcome after Tdap
No women reported AE within 30-min post-vaccination. In the
subsequent days following vaccination, pain was the most com-
mon AE reported (76.2%), most of which were mild (mean dura
tion = 2.5 days) (Tables 2 and S1–S4). Low grade fever was the sec-
ond most common AE (5.1%) (mean duration = 2.6 days). Swelling
and redness were infrequent and generally resolved within a few
days. SAE were 37 obstetrical, 4 fetal and 47 neonatal. Of 6.7% pre-
term deliveries, 84% were late preterm (GA 34–37 weeks). There
were 2 exclusions due to fetal deaths. None of the AE were deter-
mined to be related to vaccination.
3.3. Prior tetanus vaccination and risk of AE
Prior to enrolling in this study, 181 women recalled previously
having received at least one dose of a tetanus-containing vaccine
within the past five years (1 dose in 51 women, 2 doses in 94
women, and 3 doses in 36 women). Ninety-eight women received
at least one extra dose of tetanus-containing vaccine during this
current pregnancy (1 dose in 37 women, 2 doses in 60 women, 3
doses in 1 woman). Administration of prior tetanus-containing
vaccine within the previous 5 years (N = 181 women) or during
the current pregnancy (N = 98 women) did not increase the inci-
dence and severity of any solicited AEs nor resulted in prolonged
duration of the symptoms. There was also no observed increaseTable 1
Descriptive characteristics of participants in this study.
Characteristics Pregnant women
(n = 370)
Mean age (SD) 28.9 years (5.5)
Mean gestational age at vaccination (SD) 30.7 weeks (2.3)
Mode of delivery
Vaginal 209 (56.5%)
Cesarean 158 (42.7%)
No information 3 (0.8%)
Average days between vaccination and delivery (SD) 54.1 days (18.8)
Gestational age at delivery
<37 weeks 25 (6.7%)
 37 weeks 344 (93.0%)
No information 1 (0.3)
Mean infant birth weight (SD) 3087.6 g (416.2)
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women in this study (Table S5).
3.4. Differences in antibody titers at delivery
The geometric mean concentration (GMC) of anti-PT, anti-FHA
and anti-PRN IgG were similar between maternal and cord blood
pairs (Table 3). Maternal anti-PT, anti-FHA and anti-PRN IgG signif-
icantly correlated with cord values (Fig. 1). In addition, when preg-
nant women were stratified into two groups based on their
gestational age at vaccination, maternal anti-FHA IgG in the early
Tdap group who had received Tdap between 26 and 30 weeks (n
= 194) was significantly lower than those vaccinated between 31
and 36 weeks (n = 175) (p = .024, t-test) (Fig. 2). However, the
cord-to-maternal antibody ratios were significantly higher for all
three antibodies in the early Tdap group than in the late Tdap
group.
3.5. Factors affecting anti-PT, anti-PRN and anti-FHA in cord sera
Our analysis showed that maternal antibody titers at delivery
and the interval between Tdap vaccination and delivery signifi-
cantly affected the cord titers. This result is in agreement with
the significant correlation between maternal antibody levels and
cord values as shown in Section 3.4 (Fig. 1). Longer interval
between vaccination and delivery led to higher titers of antibodies
to B. pertussis antigens tested in the cord blood (Fig. 3), particularly
at 2–8 weeks prior to delivery. This effect decreased when vaccina-
tion was given between 8 and 14 weeks prior to delivery as
demonstrated by the decrease in the steepness of the curve. Taken
together, these findings suggest that vaccination at least eight
weeks prior to delivery maximized antibody titers to all three B.
pertussis antigens in the cord blood.4. Discussion
Here, we report the first of many results from a prospective,
randomized, controlled clinical trial examining the effect of Tdap
vaccination during pregnancy on infant immune responses to aP
and wP vaccines (ongoing trial). Analysis of the antibodies to B.
pertussis antigens as detected in the maternal and cord blood sug-
gests that Tdap vaccination early in the third trimester (26–30
weeks) induced significantly higher cord-to-maternal ratios than
vaccination later in the pregnancy (31–36 weeks). This is in agree-
ment with other studies, which demonstrated the benefits of early
vaccination. A study from Switzerland reported that anti-PT and
anti-FHA antibodies in the cord sera were higher after the second
trimester vaccination (up to 26 weeks of gestation) than in the
third trimester vaccination [19]. Abu Raya et al. also observed that
vaccination at 27–30 weeks elicited a significantly higher anti-PT
and anti-FHA antibody titers in cord blood than at 31–36 weeks
[20]. Our study did not reveal any significant differences in the
cord blood antibody titers among the early and the late Tdap
groups, but we note the monotonic non-linear relationship
between interval of vaccination-delivery and cord titers, which
suggests that optimal antibody transfer occurs when women are
vaccinated at least eight weeks prior to delivery.
We report a lower gradient of transplacentally transferred
ratios of all anti-B. pertussis antibodies compared to prior studies
in the USA [8] and Belgium [9], but comparable anti-FHA antibody
cord-to-maternal ratios were reported from the study in Vietnam
and Nepal [12,21]. In the Belgian and Vietnamese studies, higher
avidity of anti-PT antibodies in maternal and cord sera in Belgian
mother-infant pairs was seen compared to Vietnamese mother-
infant pairs. Thus, the efficiency of placental transfer may increaseenicity of Tdap vaccine administered during pregnancy and antibodies to
(2018), https://doi.org/10.1016/j.vaccine.2018.01.059
Table 2
Summary of the adverse events (AE) and the severe adverse events (SAE) reported among Tdap-vaccinated pregnant women and neonates in this study.
Type of reaction Description No. (%) Reported among 4636
deliveries at KCMH* in 2015 (%)
AE Localized to the injection site – Pain total 282 (76.2)
Mild 231
Moderate 51
Severe 0
– Swelling total 15 (4.1)
Mild 15
Moderate 0
Severe 0
– Redness total 5 (1.4)
Mild 5
Moderate 0
Severe 0
Systemic – Low grade fever 19 (5.1)
– Upper respiratory tract infection 1 (0.3)
– Uterine contraction 1 (0.3)
– Rash 1 (0.3)
– Itchiness 1 (0.3)
– Vertigo 1 (0.3)
– Vomiting 1 (0.3)
– Chest discomfort 1 (0.3)
Others – Gestational diabetes mellitus 10 (2.7) 8.8
– Gestational hypertension 5 (1.4) 1.9
– Thrombocytopenia 1 (0.3) 0.1
– Oligohydramnios 3 (0.8) 0.8
SAE Obstetrical – Premature delivery 25 (6.7) 12.8
– Premature contractions resulting in hospitalization 3 (0.8) N/D
– Chorioamnionitis 2 (0.5) 0.4
– Psychosis at delivery 1 (0.3) N/D
– Severe pre-eclampsia 4 (1.1) 2.1
– HELLPa syndrome 1 (0.3) 2.1
– Urinary tract infection 1 (0.3) 2.0
Fetal – Fetal death 2 (0.5) 0.8
– Congenital defectsb 2 (0.5) 2.1c
Neonatal Neonatal birth asphyxia, No. (%)
– Severe birth asphyxia (APGAR score at 1 min = 0–3) 2 (0.5) 1.3
– Mild to moderate birth asphyxia (APGAR score at 1 min = 4–7) 10 (2.7) 6.1
– Prolonged hospitalization after birthd 35 (9.5) 21.0
* KCMH = King Chulalongkorn Memorial Hospital, AE = adverse events, SAE = severe adverse events, and N/D = no data.
a Hemolysis, elevated liver enzyme levels, and low platelet levels.
b One cleft lip and cleft palate and one imperforated anus.
c Conditions of significant morbidity, which required medical and/or surgical treatment.
d Defined as hospitalization >5 days after birth as a result of an illness.
Table 3
Geometric mean concentration of anti-PT, anti-FHA and anti-PRN IgG in maternal and cord blood from Tdap-vaccinated women.
IgG Maternal, IU/ml (95%CI) Cord, IU/ml (95%CI) Ratio cord/maternal (95%CI)
Anti-PT 42.9 (38.5–47.7) 48.6 (43.5–54.4) 1.18 (1.13–1.23)
Anti-FHA 347.4 (304.5–396.3) 383.0 (336.9–435.4) 1.18 (1.12–1.24)
Anti-PRN 125.3 (99.1–158.4) 128.8 (101.8–162.9) 1.08 (1.03–1.13)*
Total 297 284 278
* After exclusion of two extreme outliers.
4 N. Wanlapakorn et al. / Vaccine xxx (2018) xxx–xxxas a result of higher antibody avidity [22]. Avidity of the antibodies
can depend on factors including the number of previous vaccine
doses, the types of vaccine antigen and natural exposure of the dis-
ease, all of which may influence the transport rate through the pla-
centa and result in different cord-to-maternal antibody ratios
among different cohorts. In addition, this study demonstrates that
timing of vaccination also impacts the cord-to-maternal antibody
ratios, with significantly higher values similar to the US study after
early third trimester vaccination [8]. Other factors such as genetics,
maternal age and existing comorbidities could potentially affect
the placental function and transplacental antibody transport,
although there were no major morbidities in this Thai pregnant
women cohort.Please cite this article in press as: Wanlapakorn N et al. Assessing the reactog
Bordetella pertussis antigens in maternal and cord sera of Thai women. VaccineVariations in the transport ratios for antibodies to the different
antigens were found in this study. The anti-PRN IgG cord-to-
maternal ratio was lowest among the three anti-B.pertussis anti-
bodies studied here. This finding is consistent with previous obser-
vations [8,9]. This might be due to the characteristics of anti-PRN
in terms of the variable proportions of IgG subclasses in response
to the antigen and the functionality of the antibody [23,24]. Future
studies evaluating IgG subclasses and the antibody functionality
may reveal the reasons for differences in transplacentally trans-
ferred ratios.
The presence of pre-existing antibodies from previous tetanus-
containing vaccine did not appear to exacerbate local or systemic
adverse reactions nor affect the pregnancy outcomes amongenicity of Tdap vaccine administered during pregnancy and antibodies to
(2018), https://doi.org/10.1016/j.vaccine.2018.01.059
Fig. 1. Correlations of anti-PT (A), anti-FHA (B) and anti-PRN (C) IgG in maternal
and cord sera. Pearson’s correlation coefficient (r) for anti-PT = 0.89; p value < .001,
for anti-FHA = 0.85; p value < .001 and for anti-PRN = 0.86; p-value < .001.
Fig. 2. Antibody levels and cord-to-maternal ratios between early Tdap-vaccinated
and late Tdap-vaccinated pregnant women. (a) Comparison of antibodies to PT, FHA
and PRN. Maternal anti-FHA was significantly higher in the late Tdap group (*p =
.024, t-test). Maternal and cord sera in the early Tdap group, n = 152; maternal sera
in the late Tdap group, n = 145; cord sera in the late Tdap group, n = 132. (b) cord-
to-maternal ratios were significantly higher in all three B. pertussis-specific
antibodies among early the Tdap group (**p < .001, t-test). Sample size in the early
Tdap group, n = 147; sample size in the late Tdap group, n = 131. Error bars
represented upper 95% confidence intervals of each value.
N. Wanlapakorn et al. / Vaccine xxx (2018) xxx–xxx 5Tdap-vaccinees in our cohort. This is in agreement with other stud-
ies which found that Tdap vaccination during pregnancy was not
associated with an increased risk of acute local and systemic reac-
tions or adversely affected pregnancy outcomes in women receiv-Please cite this article in press as: Wanlapakorn N et al. Assessing the reactog
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[25,26]. It also did not increase the risk of obstetrical and neonatal
complications [27–32], although two studies suggested a slightly
increased risk of chorioamnionitis in the Tdap-vaccinated group
[33,34]. A US study observed that non-vaccinated women had
higher preterm birth rates, incidence of small for gestational age,
and length of neonatal hospitalization than Tdap-vaccinated moth-
ers [25]. Our study observed that rates of obstetrical, neonatal and
fetal SAE in Tdap-vaccinated pregnant women were similar or even
lower compared to the general rate of AE and SAE reported at King
Chulalongkorn Memorial Hospital, possibly due to the cohort bias.
Our inclusion criteria strictly recruited women with low risk of
obstetrical complications, which could explain the lower AE in
Tdap-vaccinated group. As a tertiary care hospital and a referral
center for complicated pregnancy, the incidence of obstetrical
complications is likely to be higher compared to the general Thai
population.
In conclusion, we demonstrated that Tdap vaccination during
pregnancy was safe and well-tolerated even after recent tetanus-
containing vaccination. Our results also highlight that early vacci-enicity of Tdap vaccine administered during pregnancy and antibodies to
(2018), https://doi.org/10.1016/j.vaccine.2018.01.059
Fig. 3. The relationship between the interval of vaccination and delivery (in weeks) and smoothed function of duration in generalized additive models reflecting cord anti-PT
(a), anti-FHA (b) and anti-PRN (c). The increase in the time interval leads to the increase in the smoothed function thus leading to higher antibody titers. It is observed that the
smooth lines were steep when the interval increased between 2 and 8 weeks, but the steepness decreased between 8 and 14 weeks for all three antibodies tested. We
concluded from the graph that the best timing to maximize the cord titers was at least eight weeks prior to delivery.
6 N. Wanlapakorn et al. / Vaccine xxx (2018) xxx–xxxnation was associated with high transplacental antibody transfer,
which may help to protect newborn infants from pertussis during
the first few months of life. Further studies examining the interfer-
ence of maternal-derived antibodies in wP-vaccinated infants com-
pared to aP-vaccinated infants are ongoing.Please cite this article in press as: Wanlapakorn N et al. Assessing the reactog
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